Patents by Inventor Michiyuki Yamada

Michiyuki Yamada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL ANTI-PAD4 ANTIBODY
    Publication number: 20230192890
    Abstract: Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10?9 or less. Optionally, the anti-PAD4 antibody and a TNF? inhibitor are used in combination.
    Type: Application
    Filed: September 19, 2022
    Publication date: June 22, 2023
    Inventors: Mamoru SATO, Michiyuki YAMADA, Satoshi KANAZAWA, Masayoshi TOYOURA, Yuji SHOYA, Kenji SAITO, Chihiro YAMAZAKI
  • Anti-PAD4 antibody
    Patent number: 11447569
    Abstract: Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10?9 or less. Optionally, the anti-PAD4 antibody and a TNF? inhibitor are used in combination.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: September 20, 2022
    Assignees: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, PHARMA FOODS INTERNATIONAL CO., LTD.
    Inventors: Mamoru Sato, Michiyuki Yamada, Satoshi Kanazawa, Masayoshi Toyoura, Yuji Shoya, Kenji Saito, Chihiro Yamazaki
  • NOVEL ANTI-PAD4 ANTIBODY
    Publication number: 20180044434
    Abstract: Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10?9 or less. Optionally, the anti-PAD4 antibody and a TNF? inhibitor are used in combination.
    Type: Application
    Filed: March 7, 2016
    Publication date: February 15, 2018
    Inventors: Mamoru SATO, Michiyuki YAMADA, Satoshi KANAZAWA, Masayoshi TOYOURA, Yuji SHOYA, Kenji SAITO, Chihiro YAMAZAKI
  • Peptidyl Arginine Deiminase Type IV Inhibitor
    Publication number: 20070276040
    Abstract: A compound represented by the general formula (I) or a salt thereof is provided: wherein R1, R2 and R3 each independently represent a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, provided that at least one of R1, R2 and R3 does not represent a hydrogen atom; R4 represents an amino group which has a substituent; and R5 represents a carboxyl group which may have a substituent. Also provided is a peptidylarginine deiminase 4 inhibitor. The inhibitor can be used for the prevention and/or treatment of diseases associated with peptidylarginine deiminases (e.g., rheumatoid arthritis and multiple sclerosis).
    Type: Application
    Filed: February 3, 2005
    Publication date: November 29, 2007
    Inventors: Mamoru Sato, Toshiyuki Shimizu, Hiroshi Hashimoto, Michiyuki Yamada, Yuji Hidaka